OccuLogix suspends RHEO programme

Article

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

OccuLogix has announced that it is indefinitely suspending its RHEO System clinical development programme in dry age-related macular degeneration (AMD).

The RHEO procedure is a specific method of apheresis — a treatment in which a patient's blood is drawn outside the body and specific compounds are removed before being returned to the body.

The RHEO procedure uses patented filtering technology to remove excess levels of macro-proteins and fatty components in the blood that have been associated with AMD. These substances, which are known to thicken the blood, decrease blood flow and cause damage to capillary vessels, include LDL cholesterol, fibrinogen and alpha-2-macroglobulin.

The company cited costs and development timelines as its reasons for suspending the programme.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
Two business people in suits shake hands in front of a European Union flag. Concept image for Optegra and EssilorLuxottica acquisition, European expansion, expand into new areas of medical technology. Image credit: ©New Africa – stock.adobe.com

EssilorLuxottica acquires Optegra clinics with support from MidEuropa

Hattie Hayes
May 30th 2025
Article

The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A man undergoes evaluation in an ophthalmologist's office for uveitis. Concept image for uveitis research United Kingdom England Europe posterior and anterior eye ocular infection. Image credit: ©Maria Vitkovska – stock.adobe.com

Early uveitis detection and intervention is key to vision preservation, systemic health

Hattie Hayes
May 28th 2025
Article

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Prof Alió is a member of the Ophthalmology Times Europe Editorial Advisory Board. Here, he holds the certificate of his International Research Excellence Award. Image courtesy of Prof Jorge Alió

Jorge Alió, MD, PhD, FEBOphth, FWCRS, receives 2024 International Research Excellence Award

Hattie Hayes
May 23rd 2025
Article

Prof Alió was commended for his work in microincisional cataract surgery and accommodative IOLs for presbyopia

A single-shot, 130-degree OCTA image of the retina captured using DREAM OCT. Image courtesy of Intalight

EMA issues CE mark for DREAM OCT (Intalight)

Jordana Joy
May 22nd 2025
Article

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

© 2025 MJH Life Sciences

All rights reserved.